Drug
bupivicaine 0.25%
bupivicaine 0.25% is a pharmaceutical drug with 2 clinical trials. Currently 1 active trials ongoing.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(50%)
Terminated
1(50%)
Phase Distribution
Ph phase_1
1
50%
Ph not_applicable
1
50%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Terminated(1)
Detailed Status
Terminated1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
0.0%
Most Advanced
Phase 1
Trials by Phase
Phase 11 (50.0%)
N/A1 (50.0%)
Trials by Status
terminated150%
recruiting150%
Recent Activity
1 active trials
Showing 2 of 2
recruitingphase_1
Comparison Between Tranversus Abdominis Plane (TAP) Block With Only Bupivacaine and TAP Block With Bupivacaine Plus Ketamine in Reducing Postoperative Pain After Total Abdominal Hystrectomy
NCT07482709
terminatednot_applicable
Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures
NCT02604589
Clinical Trials (2)
Showing 2 of 2 trials
NCT07482709Phase 1
Comparison Between Tranversus Abdominis Plane (TAP) Block With Only Bupivacaine and TAP Block With Bupivacaine Plus Ketamine in Reducing Postoperative Pain After Total Abdominal Hystrectomy
NCT02604589Not Applicable
Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2